

Rahul Banerjee,, Facp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8991434/publications.pdf>

Version: 2024-02-01

56
papers

344
citations

933447

10
h-index

940533

16
g-index

58
all docs

58
docs citations

58
times ranked

475
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparable outcomes in chronic lymphocytic leukaemia (<scp>CLL</scp>) patients treated with reduced-dose ibrutinib: results from a multicentre study. <i>British Journal of Haematology</i> , 2018, 181, 259-261.	2.5	51
2	Occurrence and recall rates of fertility discussions with young breast cancer patients. <i>Supportive Care in Cancer</i> , 2016, 24, 163-171.	2.2	33
3	The Human Alpha Defensin HD5 Neutralizes JC Polyomavirus Infection by Reducing Endoplasmic Reticulum Traffic and Stabilizing the Viral Capsid. <i>Journal of Virology</i> , 2014, 88, 948-960.	3.4	27
4	Financial toxicity in hematological malignancies: a systematic review. <i>Blood Cancer Journal</i> , 2022, 12, 74.	6.2	22
5	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 668-678.	2.1	20
6	Medical student awareness of and interest in clinical informatics. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, e42-e47.	4.4	18
7	Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations?. <i>JAMA Network Open</i> , 2020, 3, e2012119.	5.9	17
8	Driving Distance and Patient-Reported Outcomes in Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2132-2138.	2.0	13
9	Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 477.e1-477.e7.	1.2	12
10	Maximizing Home Time for Persons With Cancer. <i>JCO Oncology Practice</i> , 2021, 17, 513-516.	2.9	12
11	When and How to Treat Relapsed Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 358-375.	3.8	9
12	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 2600-2611.	1.3	9
13	Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2022, 196, 1274-1277.	2.5	9
14	Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 83.e1-83.e9.	1.2	9
15	The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 132-139.	2.3	8
16	Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 7-8.	27.6	7
17	If You Book It, Will They Come? Attendance at Postdischarge Follow-Up Visits Scheduled by Inpatient Providers. <i>Journal of Hospital Medicine</i> , 2017, 12, 618-625.	1.4	7
18	Unique susceptibility of a human lung carcinoid tumor cell line to infection with BK virus. <i>Virus Research</i> , 2010, 149, 128-132.	2.2	6

#	ARTICLE	IF	CITATIONS
19	Rethinking mechanisms of neurotoxicity with BCMA directed therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103453.	4.4	6
20	Lyme Neuroborreliosis Presenting With Alexithymia and Suicide Attempts. <i>Journal of Clinical Psychiatry</i> , 2013, 74, 981.	2.2	6
21	Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3991-3995.	5.2	5
22	Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 31-37.	2.4	4
23	Benzodiazepine and zolpidem prescriptions during autologous stem cell transplantation. <i>EJHaem</i> , 2021, 2, 276-279.	1.0	3
24	Characteristics of Registered Studies of Chimeric Antigen Receptor Therapies. <i>JAMA Network Open</i> , 2021, 4, e2115668.	5.9	3
25	Digital Life Coaching for Myeloma Patients Undergoing Transplantation. <i>Blood</i> , 2020, 136, 2-3.	1.4	3
26	Virtual Conferences: Optimizing Oncology Nurses' Experience. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 699-702.	0.6	3
27	Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. <i>JMIR Formative Research</i> , 2022, 6, e33701.	1.4	3
28	A Pound of Cure Requires An Ounce (or More) of Prevention: Survivorship and Complications of Therapy for Hematologic Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 225-236.	2.3	2
29	Late effects of blood and marrow transplantation. <i>Haematologica</i> , 2017, 102, e465-e465.	3.5	2
30	Isatuximab, carfilzomib and dexamethasone (Isa-Kd) for the management of relapsed multiple myeloma. <i>Future Oncology</i> , 2021, 17, 4849-4860.	2.4	2
31	A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. <i>Bone Marrow Transplantation</i> , 2022, 57, 295-298.	2.4	2
32	Profanities, Promises, and Hospices. <i>Journal of Clinical Oncology</i> , 2019, 37, 1677-1678.	1.6	1
33	Long-Term Follow-up or Lost to Follow-up? Driving Distance and Continuity of Follow-up Care after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S304.	2.0	1
34	Driving distances and loss to follow-up after hematopoietic cell transplantation. <i>EJHaem</i> , 2021, 2, 272-275.	1.0	1
35	Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern. <i>European Journal of Cancer</i> , 2021, 157, 533-535.	2.8	1
36	Current Selection Patterns, Toxicities and Outcomes of Pre-Transplant Salvage Treatment Regimens in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Multicenter Retrospective Analysis. <i>Blood</i> , 2019, 134, 2855-2855.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes. <i>Blood</i> , 2020, 136, 5-6.	1.4	1
38	Comparable outcomes in CLL patients treated with reduced-dose ibrutinib: Results from a multi-center study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7529-7529.	1.6	1
39	Postdischarge Emergency Department Visits: Good, Bad, or Ugly?. <i>Journal of Hospital Medicine</i> , 2018, 13, 646-647.	1.4	1
40	Anthracyclines in a patient with acute leukemia and severe cardiomyopathy requiring mechanical support: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 729-732.	0.9	1
41	Severe electrolyte derangements from lysozymuria in acute myeloid leukemia. <i>EJHaem</i> , 2022, 3, 1018-1020.	1.0	1
42	Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report. <i>EJHaem</i> , 2022, 3, 1000-1002.	1.0	1
43	To Comfort, Always. <i>Journal of Palliative Medicine</i> , 2014, 17, 365-366.	1.1	0
44	Coloring the Silence. <i>Academic Medicine</i> , 2016, 91, 1088-1088.	1.6	0
45	Resilience Through Grieving Rounds. <i>Academic Medicine</i> , 2017, 92, 900.	1.6	0
46	Impact of Extremely Long Driving Distance on Distress and Physical Function in Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S257-S258.	2.0	0
47	Benzodiazepine & Zolpidem Usage in Multiple Myeloma Patients Undergoing Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S352-S353.	2.0	0
48	Feasibility of Digital Interactions with a Life Coach during Autologous Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S169.	1.2	0
49	Feasibility of digital life coaching during stem cell transplantation for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24103-e24103.	1.6	0
50	Got stage fright? A fellow-led initiative to improve cancer staging documentation.. <i>Journal of Clinical Oncology</i> , 2019, 37, 310-310.	1.6	0
51	Got Stage Fright? A Fellow-Led Initiative to Improve Cancer Staging Documentation. <i>International Journal of Cancer Care and Delivery</i> , 2021, 1, .	0.0	0
52	Randomized Study of Digital Life Coaching during Autologous Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 4023-4023.	1.4	0
53	Feasibility of a Supportive Mobile Health App for Chimeric Antigen Receptor T-Cell Therapy. <i>Blood</i> , 2021, 138, 3009-3009.	1.4	0
54	Improving performance status documentation by hematology-oncology fellows.. <i>Journal of Clinical Oncology</i> , 2020, 38, 250-250.	1.6	0

#	ARTICLE	IF	CITATIONS
55	P-132: Trial in progress: a mixed methods approach to understanding treatment experience of individuals receiving standard of care Isatuximab using patient reported, wearable, and digital health outcomes. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S107.	0.4	0
56	SNPs and PROs in myeloma: the most ambitious crossover of all time?. Bone Marrow Transplantation, 0, , .	2.4	0